James P. Allison is a scholar working on Immunology, Oncology and Molecular Biology.
According to data from OpenAlex, James P. Allison has authored 487 papers receiving a total of 72.3k indexed citations (citations by other indexed papers that have themselves been cited), including 327 papers in Immunology, 242 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in James P. Allison's work include Immunotherapy and Immune Responses (195 papers), Cancer Immunotherapy and Biomarkers (188 papers) and Immune Cell Function and Interaction (171 papers). James P. Allison is often cited by papers focused on Immunotherapy and Immune Responses (195 papers), Cancer Immunotherapy and Biomarkers (188 papers) and Immune Cell Function and Interaction (171 papers). James P. Allison collaborates with scholars based in United States, Australia and United Kingdom. James P. Allison's co-authors include Padmanee Sharma, Matthew F. Krummel, Dana R. Leach, Cynthia A. Chambers, Jedd D. Wolchok, Spencer C. Wei, Karl S. Peggs, Jackson G. Egen, Colm R. Duffy and Wendy L. Havran and has published in prestigious journals such as Nature, Science and Cell.
In The Last Decade
James P. Allison
476 papers
receiving
70.8k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The future of immune checkpoint therapy
20153.6k citationsPadmanee Sharma, James P. AllisonScienceprofile →
Restoring function in exhausted CD8 T cells during chronic viral infection
20053.1k citationsJames P. Allison et al.profile →
Enhancement of Antitumor Immunity by CTLA-4 Blockade
19962.9k citationsJames P. Allison et al.Scienceprofile →
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
20182.2k citationsJames P. Allison et al.profile →
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
19951.7k citationsJames P. Allison et al.The Journal of Experimental Medicineprofile →
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
20151.7k citationsPadmanee Sharma, James P. Allisonprofile →
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
20101.5k citationsMichael A. Curran, Hideo Yagita∥ et al.Proceedings of the National Academy of Sciencesprofile →
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
19921.4k citationsJames P. Allison et al.profile →
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
20031.2k citationsGiao Q. Phan, James Chih‐Hsin Yang et al.Proceedings of the National Academy of Sciencesprofile →
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
20131.1k citationsTyler R. Simpson, Fubin Li et al.The Journal of Experimental Medicineprofile →
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
20091.1k citationsJames P. Allison et al.Clinical Cancer Researchprofile →
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
1993974 citationsJames P. Allison et al.Scienceprofile →
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012932 citationsJames P. Allison, Lloyd J. Old et al.profile →
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017928 citationsPadmanee Sharma, James P. Allison et al.profile →
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016913 citationsJianjun Gao, Lewis Z. Shi et al.profile →
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001834 citationsJames P. Allison et al.The Journal of Experimental Medicineprofile →
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999824 citationsJames P. Allison et al.The Journal of Experimental Medicineprofile →
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
2001797 citationsCynthia A. Chambers, James P. Allison et al.profile →
Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
2005787 citationsJames P. Allison et al.Clinical Cancer Researchprofile →
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003778 citationsThomas A. Davis, Alan J. Korman et al.Proceedings of the National Academy of Sciencesprofile →
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
1996770 citationsJames P. Allison et al.The Journal of Experimental Medicineprofile →
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Countries citing papers authored by James P. Allison
Since
Specialization
Citations
This map shows the geographic impact of James P. Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James P. Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James P. Allison more than expected).
Fields of papers citing papers by James P. Allison
This network shows the impact of papers produced by James P. Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James P. Allison. The network helps show where James P. Allison may publish in the future.
Co-authorship network of co-authors of James P. Allison
This figure shows the co-authorship network connecting the top 25 collaborators of James P. Allison.
A scholar is included among the top collaborators of James P. Allison based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with James P. Allison. James P. Allison is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Malchow, Sven, Daniel S. Leventhal, Saki Nishi, et al.. (2013). Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells. Science. 339(6124). 1219–1224.251 indexed citations breakdown →
Simpson, Tyler R., Fubin Li, Welby Montalvo-Ortiz, et al.. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. The Journal of Experimental Medicine. 210(9). 1695–1710.1093 indexed citations breakdown →
Quezada, Sergio A., Tyler R. Simpson, Karl S. Peggs, et al.. (2010). Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine. 207(3). 637–650.635 indexed citations breakdown →
13.
Carthon, Bradley Curtis, Jedd D. Wolchok, Jianda Yuan, et al.. (2010). Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research. 16(10). 2861–2871.358 indexed citations breakdown →
Peggs, Karl S., Sergio A. Quezada, Cynthia A. Chambers, Alan J. Korman, & James P. Allison. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. The Journal of Experimental Medicine. 206(8). 1717–1725.726 indexed citations breakdown →
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377.1234 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.
You can learn more about the impact of James P. Allison by visiting their Pantheon page.